Golan L - Search Results

1

Fabry disease - Vascular manifestations.

Karetova D, Bultas J, Dostalova G, Palecek T, Kovarnik T, Golan L, Linhart A. Karetova D, et al. Among authors: golan l. Vasa. 2010 May;39(2):123-31. doi: 10.1024/0301-1526/a000017. Vasa. 2010. PMID: 20464667 Review.

2

Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS).

Palecek T, Honzikova J, Poupetova H, Vlaskova H, Kuchynka P, Golan L, Magage S, Linhart A. Palecek T, et al. Among authors: golan l. J Inherit Metab Dis. 2014 May;37(3):455-60. doi: 10.1007/s10545-013-9659-2. Epub 2013 Oct 31. J Inherit Metab Dis. 2014. PMID: 24173410

3

Pitfalls of X-chromosome inactivation testing in females with Fabry disease.

Řeboun M, Sikora J, Magner M, Wiederlechnerová H, Černá A, Poupětová H, Štorkánova G, Mušálková D, Dostálová G, Goláň L, Linhart A, Dvořáková L. Řeboun M, et al. Among authors: golan l. Am J Med Genet A. 2022 Jul;188(7):1979-1989. doi: 10.1002/ajmg.a.62728. Epub 2022 Mar 26. Am J Med Genet A. 2022. PMID: 35338595

4

The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment.

Vítovec M, Golán L, Roztocil K, Linhart A. Vítovec M, et al. Among authors: golan l. Vasa. 2009 Aug;38(3):238-44. doi: 10.1024/0301-1526.38.3.238. Vasa. 2009. PMID: 19736635 Clinical Trial.

5

Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.

Rob D, Marek J, Dostálová G, Goláň L, Linhart A. Rob D, et al. Among authors: golan l. PLoS One. 2016 Nov 11;11(11):e0166290. doi: 10.1371/journal.pone.0166290. eCollection 2016. PLoS One. 2016. PMID: 27835692 Free PMC article.

6

Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.

Jirásková A, Bortolussi G, Dostálová G, Eremiášová L, Golaň L, Danzig V, Linhart A, Vítek L. Jirásková A, et al. Among authors: golan l. Oxid Med Cell Longev. 2017;2017:9478946. doi: 10.1155/2017/9478946. Epub 2017 Aug 16. Oxid Med Cell Longev. 2017. PMID: 28951772 Free PMC article.

7

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.

Goláň L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, Linhart A, Musial J, Nicholls K, Gonzalez-Rodriguez D, Sharma R, Vujkovac B, Chang P, Wijatyk A. Goláň L, et al. Drug Des Devel Ther. 2015 Jul 8;9:3435-44. doi: 10.2147/DDDT.S80928. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26185417 Free PMC article. Clinical Trial.

8

Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men.

Linhart A, Jindra A, Golán L, Jáchymová M, Sedlácek K, Peleska J, Umnerová V, Bultas J, Horký K, Aschermann M. Linhart A, et al. Among authors: golan l. Br J Biomed Sci. 2002;59(2):90-4. Br J Biomed Sci. 2002. PMID: 12113410

9

How does delaying treatment affect the long-term prognosis for patients with acute myocardial infarction treated with primary coronary angioplasty?

Simek S, Lubanda JC, Aschermann M, Humhal J, Hork J, Kovarnik T, Psenika M, Golan L, Danzig V, Mrazek V. Simek S, et al. Among authors: golan l. Kardiol Pol. 2004 Aug;61(8):91-100; discussion 100. Kardiol Pol. 2004. PMID: 15457275

10

Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.

Rob D, Marek J, Dostálová G, Goláň L, Linhart A. Rob D, et al. Among authors: golan l. PLoS One. 2017 Jan 20;12(1):e0170881. doi: 10.1371/journal.pone.0170881. eCollection 2017. PLoS One. 2017. PMID: 28107535 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page